PD‐L1 antibody can specifically bind PD‐L1 molecules on tumor cells, blocking their interaction with PD‐1 receptors on T cells and disrupting this key immune checkpoint‐mediated evasion mechanism.[50] This strategy reactivates tumor‐specific immunity and restores T cell effector functions. Here, CD274 is linked to neoplasm.